摘要 |
The present invention features monoclonal antibodies LA1 or LA22 conjugated with mitomycin C, pingyangmycin or other anti-cellular agents. The present invention also features other anti-EGFR antibodies conjugated with mitomycin C or pingyangmycin. The antibodies of the present invention can be used to treat cancers, including but not limited to, those of epithelial origin, such as glioblastoma or cancer of the lung, breast, head and neck, and bladder.
|